MM&M launches New Drug Dossier

Share this article:
MM&M launches New Drug Dossier
MM&M launches New Drug Dossier

MM&M's New Drug Dossier is designed to give pharmaceutical marketers authoritative promotional and clinical insights on the latest new molecular entities in one online resource.

The New Drug Dossier culls together marketing insights from MM&M with clinical information from Monthly Prescribing Reference (MPR) to provide a valuable business intelligence tool. Every time a new drug is approved, a dossier will be compiled, and subscribers will be alerted to it by e-mail.

Each in-depth dossier consists of agency rosters, marketing strategy/execution and recent news coverage from MM&M. The tool draws on IMS Health for financial charts, the GfK US Healthcare Companies for a physician prescribing outlook and Adis R&D Insight (part of Wolters Kluwer Health) for late-stage pipeline candidates.

The full range of information also includes the following drug information from MPR: class, indication, active ingredient, pharmacology, clinical trials, adverse reactions and more.

Readers can view a sample dossier, as well as sign up for a subscription to the full New Drug Dossier archive, which contains dossiers on drugs launched in 2007. New dossiers will be based on new molecular entities, combinations thereof and select new indications. Act now for a special introductory rate.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...